Search

Learn about how first-year student get oriented to the Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK).

… Friday, September 10, 2021 Whether you’re in grade school or graduate school, late summer means it’s back to school season. It comes with the anticipation of exciting opportunities to set new goals, learn new things, and meet new people. This is not lost on the 18 first-year students who recently began

Learn how to manage menopause symptoms if you have breast cancer

… Friday, October 28, 2016 Summary The menopause symptoms that can sometimes happen as a result of breast cancer treatment are an unwelcome side effect. Memorial Sloan Kettering medical oncologist Shari Goldfarb shares her recommendations for how women can find relief. Highlights Women with breast cancer

Having two mutated copies of the TP53 gene — as opposed to a single mutated copy — is associated with worse outcomes in a blood cancer called myelodysplastic syndrome, according to a new study led by researchers at Memorial Sloan Kettering.

… Monday, August 3, 2020 Summary A large international study led by researchers at Memorial Sloan Kettering has immediate clinical relevance for risk assessment and treatment of people with myelodysplastic syndrome and acute myeloid leukemia. Considered the “guardian of the genome,” TP53 is the most commonly

An uptick in colorectal cancer in people under the age of 50 is an alarming trend that led Memorial Sloan Kettering to develop the first of its kind Center for Young Onset Colorectal Cancer in 2018. Read more.

… Monday, August 31, 2020 VIDEO | 01:05 Learn More about MSK's Center for Young Onset Colorectal Cancer Gastroenterologist Robin Mendelsohn explains how young people with colorectal cancer are treated at MSK. She also discusses ongoing research into the causes of young onset colorectal cancer. Video Details

LOXO-195, a next-generation TRK inhibitor also known as BAY 2731954, has shown signs of clinical activity in individuals with NTRK gene fusion-positive solid tumors that have become resistant to first-generation TRK inhibitors. Results from a phase I clinical trial and a US Food and Drug Administration expanded access program were presented by David Hyman, MD, the Chief of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center (MSK), at the American Association for Cancer Research (AACR) Annual Meeting 2019. This research is featured in the meeting’s press program, and findings are being presented in the “Next Generation of Clinical Trials in Molecularly Driven Therapy” minisymposium.

… Monday, April 1, 2019 LOXO-195, a next-generation TRK inhibitor also known as BAY 2731954, has shown signs of clinical activity in individuals with NTRK gene fusion-positive solid tumors that have become resistant to first-generation TRK inhibitors. Results from a phase I clinical trial and a US Food

Learn about the impact of the MSK COVID-19 Fund and The Society 2019–2020 fundraising efforts.

… Thursday, October 1, 2020 The MSK COVID-19 Fund was established in April in response to the desire of so many in our community to help during the crisis. Thanks to more than 3,000 donors, Board members, and MSK employees, the fund has raised more than $6.2 million — making a crucial difference for MSK

For the past five years, we have prospectively evaluated patients with secondary lymphedema of the upper extremity who presented for surgical consultation at Memorial Sloan Kettering Cancer Center (MSK).

… Wednesday, April 8, 2020 For the past five years, we have prospectively evaluated patients with secondary lymphedema of the upper extremity who presented for surgical consultation at Memorial Sloan Kettering Cancer Center (MSK). In our paper, published recently in the journal Cancers , we shared the

The updated versions can survive longer in the body while still packing a punch against cancer.

… Monday, December 17, 2018 Summary Scientists at Memorial Sloan Kettering are learning how to modify the structure of cancer-fighting CAR T cells to boost their performance. Chimeric antigen receptor (CAR) T cells are genetically engineered human immune cells that are designed to fight cancer. They have

Grab your popcorn and pull up a chair for these video shorts of cell signaling in early mouse development.

… Monday, October 26, 2020 A fundamental part of how embryos develop is the communication that takes place via protein receptors on the surface of cells. Signals relayed through these receptors instruct cells to assume distinct identities and eventually form individual tissues and organs. Innovative microscopy

Find out how parents can help children who have finished cancer treatment feel ready for school again.

… Friday, August 30, 2019 Summary Going back to school after finishing cancer treatment can be exciting yet anxiety-inducing for a child — and a parent. MSK neuropsychologist and child psychologist Stephen Sands has tips to help make the transition smoother. Dr. Stephen Sands Stephen Sands Getting back